These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 7116298)

  • 21. A trial of imidazole carboxamide and corynebacterium parvum in disseminated melanoma: clinical and immunologic results.
    Clunie GJ; Gough IR; Dury M; Furnival CM; Bolton PM
    Cancer; 1980 Aug; 46(3):475-9. PubMed ID: 6994866
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Randomized trial of adjuvant therapy for "high risk" primary malignant melanoma.
    Wood WC; Cosimi AB; Carey RW; Kaufman SD
    Surgery; 1978 Jun; 83(6):677-81. PubMed ID: 644461
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Controlled study with imidazole carboxamide (DTIC), DTIC + bacillus Calmette-Guérin (BCG), and DTIC + corynebacterium parvum in advanced malignant melanoma. W.H.O. Collaborating Centres for Evaluation of Methods of Diagnosis and Treatment of Melanoma.
    Tumori; 1984 Feb; 70(1):41-8. PubMed ID: 6369694
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prognostic factors in 1,521 melanoma patients with distant metastases.
    Barth A; Wanek LA; Morton DL
    J Am Coll Surg; 1995 Sep; 181(3):193-201. PubMed ID: 7670677
    [TBL] [Abstract][Full Text] [Related]  

  • 25. MAGE-A3 immunotherapeutic as adjuvant therapy for patients with resected, MAGE-A3-positive, stage III melanoma (DERMA): a double-blind, randomised, placebo-controlled, phase 3 trial.
    Dreno B; Thompson JF; Smithers BM; Santinami M; Jouary T; Gutzmer R; Levchenko E; Rutkowski P; Grob JJ; Korovin S; Drucis K; Grange F; Machet L; Hersey P; Krajsova I; Testori A; Conry R; Guillot B; Kruit WHJ; Demidov L; Thompson JA; Bondarenko I; Jaroszek J; Puig S; Cinat G; Hauschild A; Goeman JJ; van Houwelingen HC; Ulloa-Montoya F; Callegaro A; Dizier B; Spiessens B; Debois M; Brichard VG; Louahed J; Therasse P; Debruyne C; Kirkwood JM
    Lancet Oncol; 2018 Jul; 19(7):916-929. PubMed ID: 29908991
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Randomised trial of interferon alpha-2a as adjuvant therapy in resected primary melanoma thicker than 1.5 mm without clinically detectable node metastases. French Cooperative Group on Melanoma.
    Grob JJ; Dreno B; de la Salmonière P; Delaunay M; Cupissol D; Guillot B; Souteyrand P; Sassolas B; Cesarini JP; Lionnet S; Lok C; Chastang C; Bonerandi JJ
    Lancet; 1998 Jun; 351(9120):1905-10. PubMed ID: 9654256
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Adjuvant chemoimmunotherapy after regional lymphadenectomy for malignant melanoma.
    Abdi EA; Hanson J; McPherson TA
    Am J Clin Oncol; 1987 Apr; 10(2):117-22. PubMed ID: 3565312
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Low-dose adjuvant interferon for stage III malignant melanoma.
    Inman JL; Russell GB; Savage P; Levine EA
    Am Surg; 2003 Feb; 69(2):127-30. PubMed ID: 12641352
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Metastasectomy for recurrent stage IV melanoma.
    Ollila DW; Hsueh EC; Stern SL; Morton DL
    J Surg Oncol; 1999 Aug; 71(4):209-13. PubMed ID: 10440757
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Current therapy for malignant melanoma.
    Legha SS
    Semin Oncol; 1989 Feb; 16(1 Suppl 1):34-44. PubMed ID: 2465575
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Corynebacterium parvum versus BCG adjuvant immunotherapy in human malignant melanoma.
    Lipton A; Harvey HA; Lawrence B; Gottlieb R; Kukrika M; Dixon R; Graham W; Miller S; Heckard R; Schelzel D; White DS
    Cancer; 1983 Jan; 51(1):57-60. PubMed ID: 6821809
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A multifactorial analysis of melanoma. IV. Prognostic factors in 200 melanoma patients with distant metastases (stage III).
    Balch CM; Soong SJ; Murad TM; Smith JW; Maddox WA; Durant JR
    J Clin Oncol; 1983 Feb; 1(2):126-34. PubMed ID: 6668496
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prognosis of level V malignant melanoma.
    Bear HD; Neifeld JP; Kay S
    Cancer; 1985 Mar; 55(6):1167-71. PubMed ID: 3971289
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Specific active immunotherapy does not prolong survival in surgically treated patients with stage IIB malignant melanoma and may promote early recurrence.
    Hedley DW; McElwain TJ; Currie GA
    Br J Cancer; 1978 Apr; 37(4):491-6. PubMed ID: 646922
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Adjuvant therapy for melanoma.
    Sondak VK; Wolfe JA
    Curr Opin Oncol; 1997 Mar; 9(2):189-204. PubMed ID: 9161800
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Actinomycin-D plus 5-(3,3-dimethyl-1-triazeno)-imidazole-4-carboxamine (DTIC) with or without intravenous Corynebacterium parvum in metastatic malignant melanoma.
    Robidoux A; Gutterman JU; Bodey GP; Hersh EM
    Cancer; 1982 Jun; 49(11):2246-51. PubMed ID: 7042068
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Chemoimmunotherapy (DTIC and Corynebacterium parvum) for disseminated malignant melanoma.
    Karakousis CP; Didolkar MS; Han T
    Cancer Treat Rep; 1981; 65(9-10):925-6. PubMed ID: 7273032
    [No Abstract]   [Full Text] [Related]  

  • 38. Liposomal muramyl tripeptide (CGP 19835A lipid) therapy for resectable melanoma in patients who were at high risk for relapse: an update.
    Gianan MA; Kleinerman ES
    Cancer Biother Radiopharm; 1998 Oct; 13(5):363-8. PubMed ID: 10851426
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Recent advances in the care of the patient with malignant melanoma.
    Reintgen D; Balch CM; Kirkwood J; Ross M
    Ann Surg; 1997 Jan; 225(1):1-14. PubMed ID: 8998115
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cerebral metastases of malignant melanoma: contemporary treatment modalities and survival outcome.
    Panagiotou IE; Brountzos EN; Kelekis DA; Papathanasiou MA; Bafaloukos DI
    Neoplasma; 2005; 52(2):150-8. PubMed ID: 15800714
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.